|
Video: What is a Stock Split?
|
|
Kodiak Sciences is a clinical stage biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform (ABC Platform) uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, tarcocimab, is an anti-vascular endothelial growth factor antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including diabetic eye diseases, and wet age-related macular degeneration. Co. has utlized its ABC Platform to build a pipeline of product candidates in various stages of development. According to our Kodiak Sciences stock split history records, Kodiak Sciences has had 0 splits. | |
|
Kodiak Sciences (KOD) has 0 splits in our Kodiak Sciences stock split history database.
Looking at the Kodiak Sciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kodiak Sciences shares, starting with a $10,000 purchase of KOD, presented on a split-history-adjusted basis factoring in the complete Kodiak Sciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/05/2018 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$10.43 |
|
End price/share: |
$3.28 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-68.55% |
|
Average Annual Total Return: |
-18.78% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,144.69 |
|
Years: |
5.56 |
|
|
|
|
|